Infectious disease testing company NG Biotech reported on Friday the launch of the CE marked, highly sensitive COVID-19 antigen self-test Ninonasal for the detection of the Delta and Epsilon variants across Europe within the framework of international sales agreements.
Based in France, the company said the Ninonasal self-test is carried out using nasal samples. The user-friendly Ninonasal enables convenient testing on site and delivers reliable results within a few minutes. It is suitable for testing children under adult supervision.
In contrast to other rapid tests, Ninonasal is clinically confirmed in European hospitals and recognized for simple, frequent tests to detect positive cases and break chains of infection. The special test enables the detection of the alpha, beta, gamma, delta and epsilon variants, added the company.
According to the company, Ninonasal is assembled in France into kits and distributed by Boiron Laboratories for an indigenous French product.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer